Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine [Yahoo! Finance]
Moderna, Inc. (MRNA)
Last moderna, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
marinabio.com/investor-relations
Company Research
Source: Yahoo! Finance
CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an update on regulatory submissions for its investigational seasonal influenza vaccine, mRNA-1010, for adults aged 50 years and older. The Company has filed for marketing authorization with the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada, and the Therapeutic Goods Administration (TGA) in Australia. "We are proud to announce these filings for the use of our seasonal flu vaccine candidate, a major milestone for our respiratory portfolio," said Stéphane Bancel, Chief Executive Officer of Moderna. "The issue of vaccine mismatch due to virus mutations has long worried influenza experts and, as we have seen this flu season, can lead to a heightened public health burden. The agility and flexibility of mRNA technology offer the potential to more closely match evolving strains and more effectively respond to one of the world's most persistent respira
Show less
Read more
Impact Snapshot
Event Time:
MRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNA alerts
High impacting Moderna, Inc. news events
Weekly update
A roundup of the hottest topics
MRNA
News
- Moderna (MRNA) Rockets 17% on Strong Preliminary FY25 Results [Yahoo! Finance]Yahoo! Finance
- The 20 stocks most shorted by hedge funds [Seeking Alpha]Seeking Alpha
- Moderna: V940/Keytruda Data And Vaccine Revenues Drive A High-Risk Recovery Story [Seeking Alpha]Seeking Alpha
- Moderna (NASDAQ:MRNA) had its "sector perform" rating reaffirmed by analysts at Royal Bank Of Canada.MarketBeat
- Moderna (NASDAQ:MRNA) was upgraded by analysts at BMO Capital Markets from a "market perform" rating to a "buy" rating.MarketBeat
MRNA
Earnings
- 11/6/25 - Beat
MRNA
Sec Filings
- 1/12/26 - Form 8-K
- 1/6/26 - Form 4
- 1/5/26 - Form 8-K
- MRNA's page on the SEC website